274 related articles for article (PubMed ID: 27633825)
1. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
[TBL] [Abstract][Full Text] [Related]
3. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
4. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.
Araujo EG; Finzel S; Englbrecht M; Schreiber DA; Faustini F; Hueber A; Nas K; Rech J; Schett G
Ann Rheum Dis; 2015 Apr; 74(4):655-60. PubMed ID: 24336010
[TBL] [Abstract][Full Text] [Related]
5. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
Simone D; Nowik M; Gremese E; Ferraccioli GF
J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
[TBL] [Abstract][Full Text] [Related]
6. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Gladman DD; Ziouzina O; Thavaneswaran A; Chandran V
J Rheumatol; 2013 Aug; 40(8):1357-9. PubMed ID: 23818708
[TBL] [Abstract][Full Text] [Related]
7. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis.
Luo X; Deng C; Fei Y; Zhang W; Li Y; Zhang X; Zhao Y; Zeng X; Zhang F
Semin Arthritis Rheum; 2019 Feb; 48(4):626-631. PubMed ID: 29929736
[TBL] [Abstract][Full Text] [Related]
8. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
[TBL] [Abstract][Full Text] [Related]
9. Psoriatic arthritis treatment and the risk of herpes zoster.
Zisman D; Bitterman H; Shalom G; Feldhamer I; Comanesther D; Batat E; Greenberg-Dotan S; Cohen S; Cohen AD
Ann Rheum Dis; 2016 Jan; 75(1):131-5. PubMed ID: 25261573
[TBL] [Abstract][Full Text] [Related]
10. Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings.
Iannone F; Lopriore S; Bucci R; Lopalco G; Chialà A; Cantarini L; Lapadula G
J Rheumatol; 2016 May; 43(5):911-7. PubMed ID: 26980583
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
12. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
[TBL] [Abstract][Full Text] [Related]
13. Elevated C-Reactive Protein Level Predicts Earlier Treatment with Tumor Necrosis Factor-Alpha Inhibitors in Psoriatic Arthritis.
Ofer-Shiber S; Molad Y
Isr Med Assoc J; 2016 May; 18(5):279-82. PubMed ID: 27430084
[TBL] [Abstract][Full Text] [Related]
14. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
16. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
17. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
18. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
19. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
20. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
Soriano ER
J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
